GenVec, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1992-01-01
- Employees
- 15
- Market Cap
- -
- Website
- http://genvec.com
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
- Conditions
- Locally Advanced Prostate Cancer
- Interventions
- Biological: TNFeradeâ„¢ Biologic
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- GenVec
- Target Recruit Count
- 20
- Registration Number
- NCT01048151
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Radiotherapy, Cetuximab, and Injections of TNFeradeâ„¢ Biologic for Elderly or Frail Patients With Head and Neck Cancer
- Conditions
- Head and Neck CancerHead and Neck Neoplasms
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- GenVec
- Registration Number
- NCT00496236
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
A Study of TNFeradeâ„¢ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
- Conditions
- Head and Neck CancerHead and Neck Neoplasms
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- GenVec
- Registration Number
- NCT00496535
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
TNFeradeâ„¢ Biologic Plus Radiation for Metastatic Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- GenVec
- Registration Number
- NCT00261404
- Locations
- 🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States
A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard Therapies
- Conditions
- Moderate to Severe Angina Pectoris
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- GenVec
- Target Recruit Count
- 129
- Registration Number
- NCT00215696
- Locations
- 🇮🇱
Cardiac Catheterization Laboratories, Cardiology Department, Rabin Medical Center, Petah, Tikva, Israel
🇩🇰Cardiovascular Laboratory 2014, The Heart Center, University hospital Rigshospitalet, Copenhagen, Denmark
🇩🇰Skejby Sygehus, Caridology Laboratory, Århus N, Denmark
TNFeradeâ„¢ Plus Chemo/Radiation/Surgery for Rectal Cancer
- Conditions
- Rectal Cancer
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- GenVec
- Registration Number
- NCT00137878
- Locations
- 🇺🇸
Center for Cancer Research, NCI, Bethesda, Maryland, United States
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
- Conditions
- Macular Degeneration
- First Posted Date
- 2005-04-29
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- GenVec
- Registration Number
- NCT00109499
- Locations
- 🇺🇸
Florida Eye Microsurgical Institute, Inc., Boynton Beach, Florida, United States
🇺🇸UCLA - Jules Stein Eye Research Center, Los Angeles, California, United States
🇺🇸Casey Eye Institute, Portland, Oregon, United States
Study of TNFeradeâ„¢ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer
- Conditions
- Esophageal Cancer
- First Posted Date
- 2003-01-13
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- GenVec
- Registration Number
- NCT00051480
- Locations
- 🇺🇸
St. Louis University, St. Louis, Missouri, United States
🇺🇸US Oncology, Mary Crowley Center, Dallas, Texas, United States
🇺🇸UCSD Cancer Center, La Jolla, California, United States
A Study of TNFeradeâ„¢ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2003-01-13
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- GenVec
- Registration Number
- NCT00051467
- Locations
- 🇺🇸
Johns Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States
🇺🇸Mary Crowley Medical Center, Dallas, Texas, United States